![]() It also develops therapies for alpha-1 antitrypsin deficiency ocular diseases and other liver, muscle, and central nervous system disorders. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia BEAM-102 for the treatment of sickle cell disease and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. 7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatileīeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.7 Dividend Stocks to Buy When Safety is Your Top Priority.7 Stagflation Stocks to Help Navigate Periods of Low Growth.7 Commodities ETFs to Help Build a Hedge Against Inflation.7 Dividend Stocks That Earn 10% Every Month.7 Dividend Aristocrats to Help You Take the Bite Out of the Bear.10 Recession-Proof Stocks That Will Let You Wait Out the Bear.7 Stocks with the Pricing Power to Push Through High Inflation.7 Blue-Chip Dividend Stocks That Won’t be Impacted by Rising Interest Rates.7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time.7 Stocks to Buy to Outrun Rising Interest Rates.Here is a Simple 4 Stock Portfolio that Can Outperform the Market.The Five Hottest Calls From The Q2 Earnings Season.Is it Time to Throw in the Towel On Coinbase Stock?.Is Ford About To Crush Workhorse Group?.Is Uber Bait and Switching Its Way to Profitability?.MarketBeat Podcast: ESG - Profitably Invest Your Values.3 Stocks Set to Lead the Nasdaq Bull Market.Will CrowdStrike Extend Its Streak Of Topping Earnings Views?.Skyworks Solutions Is Worth A Look At These Prices.3 Blowout Earnings Reports That Could Mark Turning Points.The Trader's Guide to Equities Research.In the final minutes of trading on Friday, shares hit $17.69, a decrease of 40% in the last 12 months. īeam Global shares have fallen almost 5% since the beginning of the year. This compares to loss of $0.18 per share a year ago. The results missed Wall Street expectations.īeam Global (BEEM) Reports Q2 Loss, Tops Revenue Estimatesīeam Global (BEEM) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.19. The San Diego-based company said it had a loss of 28 cents per share. īeam Global (BEEM) on Friday reported a loss of $2.8 million in its second quarter. 12, 2022 (GLOBE NEWSWIRE) -, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative. īeam Global Reports Fiscal Q2 2022 Financial ResultsĮTSAN DIEGO, Aug. Q2 2022 Earnings Conference Call Aug16:30 ET Company Participants Desmond Wheatley - President, Chief Executive Officer and Chairman. īeam Global (BEEM) CEO Desmond Wheatley on Q2 2022 Results - Earnings Call Transcript īeam Global (BEEM) Set to Announce Quarterly Earnings on Fridayīeam Global (NASDAQ:BEEM – Get Rating) will be issuing its quarterly earnings data after the market closes on Friday, August. ![]() Maxim analyst Tate Sullivan lowered the price target for Beam Global (NASDAQ: BEEM) to $40 (an upside of 129%) from $50 while. Beam Global's Potential Timeline For Large Orders Prompts 20% Price Target Cut By This Analyst ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |